San Diego, CA, United States of America

John Chen

USPTO Granted Patents = 5 

Average Co-Inventor Count = 13.0

ph-index = 3

Forward Citations = 36(Granted Patents)


Company Filing History:


Years Active: 2015-2023

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations by John Chen in Immunotherapy

Introduction

John Chen is a prominent inventor based in San Diego, CA, known for his significant contributions to the field of immunotherapy. With a total of five patents to his name, Chen has focused on developing human antibodies that target CD27, a crucial component in immune response regulation.

Latest Patents

Chen's latest patents include groundbreaking work on neutralizing human anti-CD27 antibodies. These antibodies are designed to block the binding of CD27 to its ligand CD70, effectively neutralizing the bioactivity of CD27. This innovation has implications for T-cell proliferation, B-cell differentiation, and the overall immune response. Additionally, his methods for inhibiting naive T-cell proliferation using anti-CD27 antibodies further enhance the potential for diagnosing and treating diseases associated with CD27 activity.

Career Highlights

John Chen is currently employed at Janssen Biotech, Inc., where he continues to advance his research in immunotherapy. His work has garnered attention for its potential to improve treatment options for various diseases linked to immune system dysfunction.

Collaborations

Chen collaborates with notable colleagues, including Johan Fransson and Natalie Fursov, who contribute to the innovative research environment at Janssen Biotech.

Conclusion

John Chen's contributions to immunotherapy through his patents on anti-CD27 antibodies represent a significant advancement in the field. His work not only enhances our understanding of immune responses but also opens new avenues for therapeutic interventions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…